BIBR1532
Telomerase inhibitor / Non-competitive specific inhibitor of telomerase (IC50 = 93 nM), targeting telomerase reverse transcriptase (hTERT).1,2 Induces apoptosis in MCF-7 breast cancer cells and breast cancer stem cells3 and affected the epithelial mesenchymal transition in breast cancer stem cells4. BIBR1532 eliminated pancreatic stem cells via DNA damage and apoptosis in primary patient-derived samples.5 It significantly inhibited cell proliferation and induced apoptosis in acute myeloid leukemia stem cells.6
Biochemicals & reagents
321674-73-1
1) Damm et al. (2001), A highly selective telomerase inhibitor limiting human cancer cell proliferation; EMBO J., 20 6958 2) Pascolo et al. (2002), Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleosidic drug candidate; J. Biol. Chem., 277 15566 3) Dogan et al. (2018), Investigation of the effect of telomerase inhibitor BIBR1532 on breast cancer and breast cancer stem cells; J. Cell Biochem., 120 1282 4) Kusoglu et al. (2020), Telomerase inhibition regulates EMT mechanism in breast cancer stem cells; Gene, 759 145001 5) Walter et al. (2021), Telomerase and Pluripotency Factors Jointly Regulate Stemness n Pancreatic Cancer Stem Cells; Cancers (Basel), 13 3145 6) Rafat et al. (2022), Telomerase inhibition on acute myeloid leukemia stem cell induced apoptosis with both intrinsic and extrinsic pathways; Life Sci., 295 120402
-20°C
TARGET: Telomerase; Transcription factor -- PATHWAY: Senescence; Transcription -- RESEARCH AREA: Cancer stem cells -- DISEASE AREA: Cancer; Ageing